Ranbaxy launches Pioglitazone in US

Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the US market under an agreement with Takeda Pharmaceuticals US.

Pioglitazone hydrochloride tablet is an oral antidiabetic agent, which acts by decreasing insulin resistance and is currently distributed by Takeda Pharmaceuticals America under the name Actos.

The product is an adjunct to diet and exercise to improve glycemic controls in adults with type 2 diabetes mellitus.

Ranbaxy Pharmaceuticals North America trade sales and distribution vice president Bill Winter said Ranbaxy is making available the full range of generic pioglitazone in 15 mg, 30 mg, and 45 mg tablets.

”The introduction of generic pioglitazone hydrochloride tablets is a significant and important addition to our portfolio of antidiabetic products in the US,” Winter added.

”The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S. healthcare system.”

This entry was posted in Industry Updates, Manufacturers Updates. Bookmark the permalink.

Comments are closed.